<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04234594</url>
  </required_header>
  <id_info>
    <org_study_id>QL1203-002</org_study_id>
    <nct_id>NCT04234594</nct_id>
  </id_info>
  <brief_title>Comparing the Pharmacokinetic and Safety of QL1203 and Vectibix® in Healthy Males.</brief_title>
  <official_title>A Randomized, Double-blind and Single-dose Study to Compare the Pharmacokinetic and Safety of QL1203 and Vectibix® in Healthy Male Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qilu Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qilu Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind and parallel group study to compare the pharmacokinetic and safety&#xD;
      of QL1203 and Vectibix® in healthy males.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I,single center, randomized, double-blind，single-dose and parallel group&#xD;
      clinical trial . The primary objective is to assess the pharmacokinetic similarity of of&#xD;
      QL1203 or Vectibix® in healthy male volunteers. The secondary objective are to assess the&#xD;
      Clinical safety and immunogenicity similarity of QL1203 or Vectibix® in healthy male&#xD;
      volunteers&quot;.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC0-t )</measure>
    <time_frame>36 days</time_frame>
    <description>Area under the plasma concentration-time curve (AUC0-t ) from 0 o'clock to the last measurable concentration acquisition time t.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Healthy Males</condition>
  <arm_group>
    <arm_group_label>QL1203</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants only receive QL1203, 6mg/kg on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vectibix®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants only received Vectibix®，6 mg/kg on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QL1203</intervention_name>
    <description>6 mg/kg intravenous (IV) infusion only once，on the first day.</description>
    <arm_group_label>QL1203</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vectibix®</intervention_name>
    <description>6 mg/kg intravenous (IV) infusion only once，on the first day.</description>
    <arm_group_label>Vectibix®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects sign the informed consent form and fully understand purpose, nature, process&#xD;
             and possible adverse reactions of the study, and are able to complete the study&#xD;
             according to the study plan requirements.&#xD;
&#xD;
          -  Male,18 years to 65 years of age.&#xD;
&#xD;
          -  Weight ≧50.0 kg; body mass index (BMI) in the range of 19.0～ 26.0 kg / m^2.&#xD;
&#xD;
          -  Subjects have no history of chronic diseases or serious diseases such as&#xD;
             cardiovascular, liver, kidney, respiratory, blood and lymph, endocrine, immune,&#xD;
             psychiatric, nervous, gastrointestinal system diseases and the general health is good.&#xD;
&#xD;
          -  Clinical laboratory examination, chest X-ray, abdominal B-ultrasound,&#xD;
             electrocardiogram, physical examination, vital signs and various examinations are&#xD;
             normal or abnormal without clinical significance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects have used any biological product within 3 months prior to receiving the study&#xD;
             drug, or have used any monoclonal antibody drugs within 9 months.&#xD;
&#xD;
          -  Subjects have anallergic history to study drug or any drug component; or persons with&#xD;
             allergic history to two or more drugs and food.&#xD;
&#xD;
          -  Subjects have a history of interstitial lung disease.&#xD;
&#xD;
          -  Subjects have a history of keratitis or long-term wearing of contact lens.&#xD;
&#xD;
          -  Subjects have used any prescription drugs, over-the-counter medicines, Chinese herbal&#xD;
             medicines, and vitamins within 2 weeks before receiving the study drugs.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weiwei Ouyang, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Hospital of Guizhou Province</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shunjiang Yu, CMO</last_name>
    <phone>0531-83129659</phone>
    <email>shunjiang.yu@qilu-pharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guizhou Cancer Hospital</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <zip>550000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weiwei Ouyang, Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Kunming Medical University</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Wu, Professor</last_name>
    </contact>
    <contact_backup>
      <last_name>Li He, Professor</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 16, 2020</study_first_submitted>
  <study_first_submitted_qc>January 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 21, 2020</study_first_posted>
  <last_update_submitted>May 17, 2020</last_update_submitted>
  <last_update_submitted_qc>May 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Panitumumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

